<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525210</url>
  </required_header>
  <id_info>
    <org_study_id>503-IC</org_study_id>
    <nct_id>NCT03525210</nct_id>
    <nct_alias>NCT03482739</nct_alias>
  </id_info>
  <brief_title>Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients</brief_title>
  <official_title>An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with immunodeficiencies are at increased risk of developing persistent HPV infection&#xD;
      and as such HPV-related disease (genital warts and cancer).&#xD;
&#xD;
      In this study HIV-patients and SOT-patients will receive 3 doses of Gardasil®9. Safety,&#xD;
      tolerability and immunogenicity will be evaluated up to one month following the 3rd and last&#xD;
      dose of Gardasil®9.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label study on safety, tolerability and immunogenicity of&#xD;
      Gardasil®9 in 18 to 45 year-old HIV patients, in 18 to 55 year-old solid-organ transplant&#xD;
      (SOT) patients.&#xD;
&#xD;
      This study will enrol 140 HIV patients with CD4+ (cluster of differentiation 4) count of&#xD;
      &gt;200cells/mm² and 170 SOT patients, all of whom have not yet received a prophylactic HPV&#xD;
      vaccine. The 170 SOT patients will be equally divided over 3 different SOT patient groups,&#xD;
      namely heart, lung and kidney transplant patients. Therefore the target is to include&#xD;
      approximately 57 heart transplant patients, 57 lung transplant patients and 57 kidney&#xD;
      transplant patients. Enrolment in a SOT subgroup will be stopped when 57 patients have been&#xD;
      included unless recruitment cannot be achieved within one of the other SOT-patient&#xD;
      population.&#xD;
&#xD;
      All enrolled subjects will receive a 3-dose regimen (Day 1, Month 2, and Month 6) of&#xD;
      GARDASIL®9. Serum samples will be collected on Day 1 and Month 7 for anti-HPV 6, 11, 16, 18,&#xD;
      31, 33, 45, 52, and 58 antibody determination.. The time point for comparison of immune&#xD;
      responses will be Month 7, or approximately 4 weeks after the administration of the third&#xD;
      dose. The safety/tolerability profile of the vaccine will be evaluated in all subjects in the&#xD;
      study. Safety information will be collected on Day 1 through 1 month following the third&#xD;
      vaccination or for a total of approximately 7 months for each subject.&#xD;
&#xD;
      The immunogenicity and the safety data will be analyzed per group of patients. More&#xD;
      specifically a separate analysis of HIV and SOT patients is planned, since it is expected&#xD;
      that the immunosuppressive therapy of SOT patients might have a more profound effect on&#xD;
      immunogenicity following vaccination.&#xD;
&#xD;
      This study will provide a comparison of immunogenicity of Gardasil ®9 in immunocompromised&#xD;
      patients, with historical controls (15, 18). The number of subjects to be enrolled in the&#xD;
      study was determined based on the primary immunogenicity objective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Following 3 Doses of 9-valent HPV Vaccines</measure>
    <time_frame>7 months (for each subject)</time_frame>
    <description>Seroconversion rates of neutralizing antibodies against each HPV vaccine genotypes (6/11/16/18/31/33/45/52/58) one month after completion of a three doses schedule (0, 2 and 6 months) in patients seronegative at baseline for these antibodies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions Following 9-valent HPV Vaccination</measure>
    <time_frame>7 months (for each subject)</time_frame>
    <description>Number and percentage of subjects with local and systemic sollicited (up to 7 days following each vaccination) and unsollicited adverse events (up to 1 month after the 3rd HPV vaccine) will be analysed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Human Papilloma Virus</condition>
  <condition>Hiv</condition>
  <condition>Organ Transplants</condition>
  <arm_group>
    <arm_group_label>HIV patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All HIV patients will receive the study vaccines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOT patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All SOT patients will receive the study vaccines</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>9-valent HPV vaccine</intervention_name>
    <description>Vaccination</description>
    <arm_group_label>HIV patients</arm_group_label>
    <arm_group_label>SOT patients</arm_group_label>
    <other_name>Gardasil9</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Independent Ethics Committee (IEC)-approved written informed consent form (ICF) must&#xD;
             be obtained from the subject prior to any study-related procedures (including&#xD;
             discontinuation of prohibited medication, if applicable) by the subject is given as&#xD;
             required by local law.&#xD;
&#xD;
          2. Subject (man or woman) is between the age of 18 years and 0 days and 45 years and 365&#xD;
             days for HIV patients, between 18 years and 0 days and 55 years and 365 days for&#xD;
             transplant patients at time of signing the ICF&#xD;
&#xD;
          3. Subject is able to understand and adhere to the study procedures (e.g., is not&#xD;
             planning to relocate far from the investigational centre during the study period); is&#xD;
             able to read, understand, and complete the vaccination diary; is able to understand&#xD;
             the risks involved with the study; and voluntarily agrees to participate in the study&#xD;
             by giving written informed consent.&#xD;
&#xD;
          4. * Since the first day of their last menstrual period through Day 1, female subjects&#xD;
             have not had sex with males or has had sex with males and used effective contraception&#xD;
             with no failures (an example of a failure is a male condom that ruptures during sexual&#xD;
             intercourse). Effective contraception is defined as a marketed, approved contraceptive&#xD;
             product that the subject has used per the manufacturer's instructions with every act&#xD;
             of sexual intercourse. The subject understands and agrees that during the Day 1&#xD;
             through Month 7 period, she should not have sexual intercourse with males without&#xD;
             effective contraception. The use of the rhythm method alone, withdrawal alone, and&#xD;
             emergency contraception, are not acceptable methods per the protocol. Subjects who&#xD;
             have reached menopause, undergone hysterectomy, bilateral oophorectomy, or bilateral&#xD;
             tubal ligation are eligible without the use of contraceptives. Postmenopausal status&#xD;
             is defined as: (1) No menses for &gt;1 year but &lt;3 years and confirmed by follicle&#xD;
             stimulating hormone (FSH) levels elevated into the postmenopausal range, or (2) no&#xD;
             menses for at least 3 years.&#xD;
&#xD;
          5. * Subject has had no temperature ≥37.8°C within 24 hours prior to the first injection.&#xD;
&#xD;
          6. Patient considerations&#xD;
&#xD;
               -  HIV patients: have CD4+ T cell count of &gt;200 cells/mm² at the last control (less&#xD;
                  than 12 months ago).&#xD;
&#xD;
               -  SOT patients received their organ transplantation ≥12 months prior to vaccination&#xD;
                  and has been stable in the past 6 months (i.e. no acute rejection or other&#xD;
                  immunological reactions).&#xD;
&#xD;
          7. Apart from having HIV or received a solid organ transplant, the subject is in stable&#xD;
             condition (i.e. no graft-versus-host disease or other immunological reactions) and is&#xD;
             judged to be in good physical health on the basis of medical history, physical&#xD;
             examination (if deemed necessary), and laboratory testing&#xD;
&#xD;
          8. Subject agrees to provide study personnel with a primary telephone number as well as&#xD;
             an alternate telephone number for follow-up purposes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a history of an abnormal Pap test or abnormal cervical biopsy results&#xD;
             (showing cervical intraepithelial neoplasia or worse) or cervical disease (i.e.,&#xD;
             surgical treatment for cervical lesions).&#xD;
&#xD;
          2. Subject has history of genital warts, Vulvar Intraepithelial Neoplasia or Vaginal&#xD;
             Intraepithelial Neoplasia.&#xD;
&#xD;
          3. Subject has a history of a positive test for HPV.&#xD;
&#xD;
          4. Subject has a history of known prior vaccination with an HPV vaccine, i.e., received a&#xD;
             marketed HPV vaccine, or has participated in an HPV vaccine clinical study and has&#xD;
             received either active agent or placebo.&#xD;
&#xD;
          5. Subject is pregnant (as determined by serum or urine pregnancy test).&#xD;
&#xD;
          6. Subject is, at the time of signing ICF, a user of recreational or illicit drugs or has&#xD;
             had a recent history (within the last year) of drug or alcohol abuse or dependence.&#xD;
             Alcohol abusers are defined as those who drink despite recurrent social,&#xD;
             interpersonal, and/or legal problems as a result of alcohol use.&#xD;
&#xD;
          7. Subject has a history of severe allergic reaction, including known allergy to any&#xD;
             vaccine component, including aluminum, yeast, or BENZONASE® (nuclease, Nycomed [used&#xD;
             to remove residual nucleic acids from this and other vaccines]) (e.g., swelling of the&#xD;
             mouth and throat, difficulty breathing, hypotension or shock) that met the criteria&#xD;
             for serious adverse experiences defined in this protocol.&#xD;
&#xD;
          8. Patient's condition&#xD;
&#xD;
               1. Exclusion criterion only for HIV patients: Subject has had a splenectomy, or has&#xD;
                  been diagnosed as having a congenital immunodeficiency, lymphoma, leukaemia,&#xD;
                  systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid&#xD;
                  arthritis, inflammatory bowel disease, or other autoimmune or immunosuppressive&#xD;
                  condition, or has a history of any disease, which, in the investigator's opinion,&#xD;
                  may confound the results of the study or pose an additional risk to the subject.&#xD;
&#xD;
               2. Exclusion criterion only for SOT patients: Subject has had a splenectomy, or has&#xD;
                  been diagnosed as having a congenital or acquired immunodeficiency, HIV&#xD;
                  infection, lymphoma, leukaemia, systemic lupus erythematosus, rheumatoid&#xD;
                  arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other&#xD;
                  autoimmune or immunosuppressive condition, or has a history of any disease,&#xD;
                  which, in the investigator's opinion, may confound the results of the study or&#xD;
                  pose an additional risk to the subject.&#xD;
&#xD;
          9. Patient's medication&#xD;
&#xD;
               1. Exclusion criterion only for HIV patients: Subject is receiving or has received&#xD;
                  in the year prior to enrolment the following immunosuppressive therapies:&#xD;
                  radiation therapy, cyclophosphamide, azathioprine, methotrexate, any&#xD;
                  chemotherapy, cyclosporin, leflunomide (tumour necrosis factor-α antagonists,&#xD;
                  monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma&#xD;
                  globulin, antilymphocyte sera, or other therapy known to interfere with the&#xD;
                  immune response. With regard to systemic corticosteroids, a subject will be&#xD;
                  excluded if she is currently receiving steroid therapy, has recently (defined as&#xD;
                  within 2 weeks of enrolment) received such therapy, or has received 2 or more&#xD;
                  courses of high dose corticosteroids (≥20mg/day of prednisone [or equivalent]&#xD;
                  orally or parenterally) lasting at least 1 week in duration in the year prior to&#xD;
                  enrolment. Subjects using inhaled, nasal, or topical corticosteroids are&#xD;
                  considered eligible for the study&#xD;
&#xD;
               2. Exclusion criterion only for SOT patients: Subject is receiving or has received&#xD;
                  in the year prior to enrolment the following immunosuppressive therapies:&#xD;
                  radiation therapy, cyclophosphamide, azathioprine, methotrexate, any&#xD;
                  chemotherapy, cyclosporin, leflunomide (tumour necrosis factor-α antagonists,&#xD;
                  monoclonal antibody therapies (including rituximab [Rituxan]) ,intravenous gamma&#xD;
                  globulin or antilymphocyte sera.&#xD;
&#xD;
         10. Subject has received any immune globulin or blood-derived product within the 3 months&#xD;
             prior to the Day 1 vaccination, or plans to receive any such product during Day 1&#xD;
             through Month 7 of the study.&#xD;
&#xD;
         11. Subject has thrombocytopenia or other coagulation disorder that would contraindicate&#xD;
             intramuscular injections.&#xD;
&#xD;
         12. * Subject has received inactivated vaccines within 14 days prior to the Day 1&#xD;
             vaccination or has received replicating (live) vaccines within 28 days prior to the&#xD;
             Day 1 vaccination. The administration of the inactivated influenza vaccine is allowed&#xD;
             7 days prior to or after each study vaccine.&#xD;
&#xD;
         13. Subject is concurrently enrolled in a clinical study of investigational agent.&#xD;
&#xD;
         14. Subject has a history or current condition of which the investigator believes that it&#xD;
             might interfere with the study vaccines.&#xD;
&#xD;
         15. Subject has a history or current evidence of any condition, therapy, lab abnormality&#xD;
             or other circumstance that might confound the results of the study, or interfere with&#xD;
             the subject's participation for the full duration of the study, such that it is not in&#xD;
             the best interest of the subject to participate.&#xD;
&#xD;
         16. Subject is or has an immediate family member (e.g., spouse, parent/legal guardian,&#xD;
             sibling or child) who is investigational site or Sponsor staff directly involved with&#xD;
             this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Vandermeulen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <results_first_submitted>October 23, 2020</results_first_submitted>
  <results_first_submitted_qc>November 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2020</results_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03525210/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is a single center, open-label, investigator-initiated phase III study (protocol V503-044-IC, NCT03525210) in HIV patients and SOT recipients One hundred HIV patients (age: 18-45 years) and 171 SOT (kidney, heart, lung transplant) patients (age: 18-55 years) were enrolled between April 2018 and January 2019 in the outpatient clinic of the University Hospitals Leuven, Belgium</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>HIV Patients</title>
          <description>All HIV patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination</description>
        </group>
        <group group_id="P2">
          <title>SOT Patients</title>
          <description>All SOT patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIV Patients</title>
          <description>All HIV patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination</description>
        </group>
        <group group_id="B2">
          <title>SOT Patients</title>
          <description>All SOT patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="271"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B2" value="46" lower_limit="19" upper_limit="55"/>
                    <measurement group_id="B3" value="42" lower_limit="18" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Following 3 Doses of 9-valent HPV Vaccines</title>
        <description>Seroconversion rates of neutralizing antibodies against each HPV vaccine genotypes (6/11/16/18/31/33/45/52/58) one month after completion of a three doses schedule (0, 2 and 6 months) in patients seronegative at baseline for these antibodies.</description>
        <time_frame>7 months (for each subject)</time_frame>
        <population>were seronegative to the appropriate HPV type at Day 1, had serology results based on acceptable day ranges and had no protocol deviations that could interfere with the subject's vaccine as judged by the principal investigator.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV Patients</title>
            <description>All HIV patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination&#xD;
Number and proportion of patients with adverse events.</description>
          </group>
          <group group_id="O2">
            <title>SOT Patients</title>
            <description>All SOT patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination&#xD;
Number and proportion of patients with adverse events.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Following 3 Doses of 9-valent HPV Vaccines</title>
          <description>Seroconversion rates of neutralizing antibodies against each HPV vaccine genotypes (6/11/16/18/31/33/45/52/58) one month after completion of a three doses schedule (0, 2 and 6 months) in patients seronegative at baseline for these antibodies.</description>
          <population>were seronegative to the appropriate HPV type at Day 1, had serology results based on acceptable day ranges and had no protocol deviations that could interfere with the subject's vaccine as judged by the principal investigator.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-HPV6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.2" upper_limit="100"/>
                    <measurement group_id="O2" value="64.2" lower_limit="55.8" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.3" upper_limit="100"/>
                    <measurement group_id="O2" value="70.7" lower_limit="62.7" upper_limit="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.3" upper_limit="100"/>
                    <measurement group_id="O2" value="69.1" lower_limit="61.0" upper_limit="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.6" upper_limit="100"/>
                    <measurement group_id="O2" value="51.5" lower_limit="43.2" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 31</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.4" upper_limit="100"/>
                    <measurement group_id="O2" value="55.9" lower_limit="47.6" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 33</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.1" upper_limit="100"/>
                    <measurement group_id="O2" value="66.9" lower_limit="58.8" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.3" upper_limit="100"/>
                    <measurement group_id="O2" value="46.0" lower_limit="37.8" upper_limit="54.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95.8" upper_limit="100"/>
                    <measurement group_id="O2" value="65.3" lower_limit="57.1" upper_limit="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HPV 58</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.9" upper_limit="100"/>
                    <measurement group_id="O2" value="72.0" lower_limit="64.1" upper_limit="79.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Reactions Following 9-valent HPV Vaccination</title>
        <description>Number and percentage of subjects with local and systemic sollicited (up to 7 days following each vaccination) and unsollicited adverse events (up to 1 month after the 3rd HPV vaccine) will be analysed</description>
        <time_frame>7 months (for each subject)</time_frame>
        <population>Patients with HIV or solid organ transplant who received at least one study vaccine and had at least one follow-up visit for AEs.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV Patients</title>
            <description>All HIV patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination</description>
          </group>
          <group group_id="O2">
            <title>SOT Patients</title>
            <description>All SOT patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Reactions Following 9-valent HPV Vaccination</title>
          <description>Number and percentage of subjects with local and systemic sollicited (up to 7 days following each vaccination) and unsollicited adverse events (up to 1 month after the 3rd HPV vaccine) will be analysed</description>
          <population>Patients with HIV or solid organ transplant who received at least one study vaccine and had at least one follow-up visit for AEs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time frame: 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HIV Patients</title>
          <description>All HIV patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination&#xD;
Number and percentage of patients with adverse events. One patient stopped after the first dose and no safety information could be retrieved.</description>
        </group>
        <group group_id="E2">
          <title>SOT Patients</title>
          <description>All SOT patients will receive the study vaccines&#xD;
9-valent HPV vaccine: Vaccination&#xD;
Number and percentage of patients with adverse events. One patient stopped after the first dose and no safety information could be retrieved.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abbdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute rejection transplant organ</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever without focus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Gastro-intestinal infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Respiratory infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Skin infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Generalized infections</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Urogenital infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture tibia plateau</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dysregulation glycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthrosis neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Relapse renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Cyst in transplant kidney</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Hemorrhage in adenohypophysis macroadenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol Abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pathology of the kidney</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory pathology</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Burn-out</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="67" subjects_affected="67" subjects_at_risk="99"/>
                <counts group_id="E2" events="93" subjects_affected="93" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="170"/>
              </event>
              <event>
                <sub_title>injection site erythema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="99"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="170"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No healthy control group was included in this study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Head of Leuven University Vaccinology Center</name_or_title>
      <organization>KU Leuven / UZ Leuven</organization>
      <phone>+32 16 321 078</phone>
      <email>luvac@kuleuven.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

